Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 12/06 03:51:00 am
8262.5 GBX   +0.87%
03:33aLONDON STOCK EXCHANGE : FTSE 100 gains after choppy week with oil stocks in lead
RE
02:06aCovid-19 Vaccination - Federal Govt Approves Booster Dose
AQ
01:21aPfizer accused of funding anti- AstraZeneca info
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca Says FDA Granted Breakthrough-Therapy Designation for Cancer Treatment Enhertu

10/04/2021 | 12:32am EST

By Anthony O. Goriainoff

AstraZeneca PLC said Monday that the U.S. Food and Drug Administration granted its cancer treatment Enhertu a breakthrough-therapy designation for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

HER2 refers to a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2.

The U.K. pharmaceutical company said that the FDA granted the designation based on the DESTINY-Breast03 Phase 3 trial, and that this is Enhertu's second BTD in breast cancer, bringing the total number to four.

The company said Enhertu's trial showed it reduced the risk of disease progression or death by 72% in patients with HER2-positive metastatic breast cancer.

The BTD designation is designed to accelerate the development and the regulatory review of potential new medicines that are intended to treat a serious condition, the company said.

Enhertu is a HER2-directed antibody drug conjugate that is being developed jointly by AstraZeneca and Daiichi Sankyo Co.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

10-04-21 0232ET

All news about ASTRAZENECA PLC
03:33aLONDON STOCK EXCHANGE : FTSE 100 gains after choppy week with oil stocks in lead
RE
02:06aCovid-19 Vaccination - Federal Govt Approves Booster Dose
AQ
01:21aPfizer accused of funding anti- AstraZeneca info
AQ
01:00aCOVID shots are finally arriving, but Africa can't get them all into arms
RE
12/05Pfizer Denies Claims of Funding Misinformation Against AstraZeneca's COVID-19 Jab
MT
12/04Covid-19 - Nigeria Approves Booster Doses for Enhanced Protection
AQ
12/03AstraZeneca Explores Listing of Newly-Created Vaccines Unit
MT
12/03AstraZeneca Reportedly Weighs Listing of Newly-Created Vaccines Unit
MT
12/03European Stocks Close Lower After Disappointing US Jobs Data
MT
12/03AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Undersco..
CI
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 919 M - -
Net income 2021 3 423 M - -
Net Debt 2021 25 253 M - -
P/E ratio 2021 36,9x
Yield 2021 2,60%
Capitalization 168 B 168 B -
EV / Sales 2021 5,38x
EV / Sales 2022 4,40x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 108,38 $
Average target price 137,48 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC11.84%167 779
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641